UBS AM
OCUL icon

UBS AM’s Ocular Therapeutix OCUL Stock Holding History

UBS AM’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.82M Sell
287,158
-21,748
-7% -$197K ﹤0.01% 1904
2026
Q1 		$2.62M Buy
308,906
+1,159
+0.4% +$11K ﹤0.01% 1912
2025
Q4 		$3.74M Buy
307,747
+106,488
+53% +$1.29M ﹤0.01% 1604
2025
Q3 		$2.35M Sell
201,259
-115,017
-36% -$1.38M ﹤0.01% 1682
2025
Q2 		$2.94M Buy
316,276
+103,324
+49% +$809K ﹤0.01% 1965
2025
Q1 		$1.56M Sell
212,952
-5,636
-3% -$43.3K ﹤0.01% 2106
2024
Q4 		$1.87M Buy
218,588
+70,904
+48% +$692K ﹤0.01% 2086
2024
Q3 		$1.28M Sell
147,684
-38,376
-21% -$316K ﹤0.01% 2266
2024
Q2 		$1.27M Buy
+186,060
New +$1.15M ﹤0.01% 2250
2022
Q2 		– Sell
-101,123
Closed -$501K – 2743
2022
Q1 		$501K Buy
101,123
+22,065
+28% +$122K ﹤0.01% 2461
2021
Q4 		$551K Buy
79,058
+10,437
+15% +$81.1K ﹤0.01% 2519
2021
Q3 		$686K Sell
68,621
-6,599
-9% -$74.1K ﹤0.01% 2345
2021
Q2 		$1.07M Buy
75,220
+12,772
+20% +$194K ﹤0.01% 2172
2021
Q1 		$1.02M Buy
62,448
+12,311
+25% +$237K ﹤0.01% 2079
2020
Q4 		$1.04M Buy
+50,137
New +$745K ﹤0.01% 1970

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM's OCUL Position: Q2 2026 in Review

UBS AM reduced its Ocular Therapeutix (OCUL) stake by 7% in Q2 2026, selling an estimated $197K and leaving 287,158 shares worth $2.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1904.

UBS AM first reported a position in OCUL in Q4 2020 and has held it in 15 quarters since. The position peaked at $3.74M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • UBS AM held 287,158 shares of Ocular Therapeutix worth $2.82M as of Q2 2026.
  • UBS AM sold 21,748 Ocular Therapeutix shares in Q2 2026, an estimated $197K.
  • Ocular Therapeutix made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1904 holding.
  • UBS AM first reported a position in Ocular Therapeutix in Q4 2020 and has held it in 15 quarters since.
  • UBS AM's Ocular Therapeutix position peaked at $3.74M in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.